RAPT Therapeutics shareholders approve 1:8 reverse stock split and 2025 equity plan

RAPT Therapeutics, Inc.

Stockholders approved a reverse stock split of common stock at a ratio of one-for-eight.
2025 Equity Incentive Plan approved with 76.7M votes for, 23.8M against.
ESPP amended: removed evergreen provision, increased authorized shares by 4 million.
Dr. Michael F. Giordano elected as Class III director with 77.0M votes for.
Say-on-pay passed; Board sets future advisory votes every year.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.